A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Key facts

Sponsor

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Bristol-Myers Squibb

Intervention

Deucravacitinib(drug)

Enrollment

60 enrolled

Eligibility

5-17 years · All sexes

Timeline

2025 – 2031

Study locations (30)

• Local Institution - 0038, Lancaster, California, United States
• Local Institution - 0020, Chicago, Illinois, United States
• Local Institution - 0023, Indianapolis, Indiana, United States
• Local Institution - 0059, North New Hyde Park, New York, United States
• Local Institution - 0065, Cincinnati, Ohio, United States
• Local Institution - 0066, Cleveland, Ohio, United States
• Local Institution - 0036, Austin, Texas, United States
• Local Institution - 0068, Fortaleza, Ceará, Brazil
• Local Institution - 0032, Cuiabá, Mato Grosso, Brazil
• Local Institution - 0030, Belo Horizonte, Minas Gerais, Brazil
• Local Institution - 0013, Curitiba, Paraná, Brazil
• Local Institution - 0072, Curitiba, Paraná, Brazil
• Local Institution - 0007, Recife, Pernambuco, Brazil
• Local Institution - 0033, Porto Alegre, Rio Grande do Sul, Brazil
• LMK Serviços Médicos S/S, Porto Alegre, Rio Grande do Sul, Brazil
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Psoriasis-related juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06751238
  Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
  Novartis Pharmaceuticals
• RECRUITINGPHASE3NCT06668181
  An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
  UCB Biopharma SRL
• RECRUITINGPHASE3NCT06100744
  A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
  AbbVie
• RECRUITINGPHASE3NCT05767047
  A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
  Amgen
• ACTIVE NOT RECRUITINGPHASE3NCT05083182
  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
  Janssen Research & Development, LLC
• RECRUITINGPHASE3NCT04804553
  Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
  Amgen
• ACTIVE NOT RECRUITINGPHASE3NCT04527380
  A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
  Eli Lilly and Company

See all trials for Psoriasis-related juvenile idiopathic arthritis →